Eli Lilly and Company (NYSE:LLY) Shares Sold by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.4% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 159,203 shares of the company's stock after selling 5,631 shares during the quarter. Cambridge Investment Research Advisors Inc.'s holdings in Eli Lilly and Company were worth $122,904,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the business. Capital Advantage Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter valued at $441,000. Castle Hook Partners LP acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth about $69,732,000. Cetera Investment Advisers boosted its position in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Cetera Investment Advisers now owns 232,598 shares of the company's stock worth $179,565,000 after buying an additional 5,806 shares during the period. Blue Capital Inc. purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $3,088,000. Finally, Cantor Fitzgerald L. P. acquired a new position in Eli Lilly and Company during the 4th quarter worth approximately $3,510,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $24.70 during midday trading on Thursday, hitting $752.02. 6,156,100 shares of the stock traded hands, compared to its average volume of 3,505,620. The business's 50 day moving average price is $818.04 and its two-hundred day moving average price is $813.77. The firm has a market capitalization of $712.72 billion, a PE ratio of 64.22, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the firm earned $2.58 earnings per share. The company's revenue for the quarter was up 45.2% on a year-over-year basis. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be given a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.80%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

Wall Street Analysts Forecast Growth

LLY has been the subject of several recent research reports. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Hsbc Global Res lowered Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Truist Financial increased their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $1,002.80.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.